Sobi Reports Significant Growth and Strategic Advancements in 2025 Financial Year

Swedish Orphan Biovitrum AB, commonly referred to as Sobi®, has recently disclosed its financial performance for the fourth quarter and the entire fiscal year of 2025. The results showcase not only substantial growth in revenue but also noteworthy strategic progress. This report paints an optimistic picture for the company's future, reflecting their commitment to improving the lives of individuals with rare diseases.

Fourth Quarter Highlights

In the fourth quarter of 2025, Sobi achieved a total revenue increase of 5% compared to the previous year, translating to SEK 7,821 million. When adjusted for constant exchange rates, this figure rises to a 16% increase. Notably, the haematology sector experienced remarkable growth, reporting a 25% increase at constant currency rates, with revenues amounting to SEK 5,143 million. The strong performance was bolstered by the outstanding sales of the drugs Altuvoct, generating SEK 1,023 million, and Doptelet, which fetched SEK 1,508 million. However, this was partially offset by a decline in sales of Vonjo, which brought in SEK 327 million.

In the immunology segment, revenue rose by 2% at constant exchange rates, totaling SEK 2,337 million. This increase was fueled by robust sales of Gamifant, which contributed SEK 763 million, and Kineret’s sales reaching SEK 741 million. However, a decline in Beyfortus royalties, which fell to SEK 849 million from last year's SEK 1,207 million, dampened the overall increase.

Additionally, revenue from Sobi's strategic portfolio surged by an impressive 37%, reaching SEK 5,059 million, further indicating the company’s operational strengths in 2025. The adjusted EBITA margin also saw a rise to 41%, up from 34% in the previous year, excluding certain items affecting comparability.

Full Year Overview

For the entirety of 2025, Sobi reported an 8% increase in total revenue, equating to SEK 28,238 million, compared to SEK 26,027 million in 2024. The haematology segment particularly stood out with a 23% increase in revenue, while immunology displayed modest growth of 1%. The adjusted EBITA margin for the full year was recorded at 40%, compared to 36% from the previous year.

Interestingly, despite the overall financial upswing, the board recommended not to issue dividends for 2025, signaling a reinvestment strategy aimed at further growth.

Looking Ahead: Outlook for 2026

As Sobi turns its gaze toward 2026, the company anticipates a continued increase in revenue at a low double-digit percentage rate when adjusted for constant exchange rates. Furthermore, an adjusted EBITA margin is expected to remain in the mid-30s percentage range of revenue, showcasing a commitment to maintaining profitability amid expanding operations.

To discuss these results in detail, Sobi invites investors, analysts, and media representatives to participate in a conference call where further insights and a Q&A session will be conducted. The presentation will be available to the public on Sobi's website both live and on-demand.

About Sobi

Sobi is a global biopharma company dedicated to unlocking the potential of breakthrough innovations, significantly enhancing the quality of life for those afflicted by rare diseases. With a workforce of approximately 1,900 professionals operating across Europe, North America, the Middle East, Asia, and Australia, Sobi generated a revenue of SEK 28 billion in 2025. For investors, Sobi's shares are traded on Nasdaq Stockholm under the ticker symbol STOSOBI.

For further updates, visit Sobi's official website and its LinkedIn page, where more information on their innovations and corporate activities can be found.